Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity

Behavioural Brain Research

Volumn 136, Issue 1, 2002, Pages 267-275

  Eells, J B ^a   Lipska, B K ^b   Yeung, S K ^a   Misler, J A ^a   Nikodem, V M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Amphetamine; Dopamine; Nurr1; Schizophrenia; Stress

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; DIZOCILPINE; DOPAMINE; HALOPERIDOL; NORADRENALIN; SODIUM CHLORIDE;

ALLELE; ANIMAL BEHAVIOR; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; HETEROZYGOSITY; LIMBIC CORTEX; LOCOMOTION; MALE; MESENCEPHALON; MOUSE; NEUROTRANSMISSION; NEWBORN; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; OPEN FIELD BEHAVIOR; PREFRONTAL CORTEX; PRIORITY JOURNAL; STRESS;

AMPHETAMINE; ANIMALS; BRAIN CHEMISTRY; CATECHOLAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; DNA-BINDING PROTEINS; DOPAMINE; HETEROZYGOTE; LIMBIC SYSTEM; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STRESS, PSYCHOLOGICAL; TRANSCRIPTION FACTORS;

EID: 0037126171     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00185-7     Document Type: Article

References (40)

1. Al-Amin H.A., Weinberger D.R., Lipska B.K. Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav. Pharmacol. 11:2000;269-278.
2. Brose N., O'Neill R.D., Boutelle M.G., Anderson S.M., Fillenz M. Effects of an anxiogenic benzodiazepine receptor ligand on motor activity and dopamine release in nucleus accumbens and striatum in the rat. J. Neurosci. 7:1987;2917-2926.
3. Buervenich S., Carmine A., Arvidsson M., Xiang F., Zhang Z., Sydow O., Jonsson E.G., Sedvall G.C., Leonard S., Ross R.G., Freedman R., Chowdari K.V., Nimgaonkar V.L., Perlmann T., Anvret M., Olson L. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am. J. Med. Genet. 96:2000;808-813.
4. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260.
5. Castillo S.O., Baffi J.S., Palkovits M., Goldstein D.S., Kopin I.J., Witta J., Magnuson M.A., Nikodem V.M. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell. Neurosci. 11:1998;36-46.
6. Chen Y.H., Tsai M.T., Shaw C.K., Chen C.H. Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients. Am. J. Med. Genet. 105:2001;753-757.
7. Eells J.B., Witta J., Otridge J.B., Zuffova E., Nikodem V.M. Structure and function of the Nur77 subfamily, a unique class of hormone nuclear receptors. Curr. Genomics. 1:2000;135-152.
8. Eells JB, Yeung SK, Nikodem VM. Dopamine neurons heterozygous for the Nurr1-Null allele have reduced survival in vitro, Neurosci. Res. Commun. 2002;30:173-83.
9. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates. 1997;Academic press, San Diego, CA.
10. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res. Brain Res. Rev. 26:1998;148-153.
11. Holmes C., Eisenhofer G., Goldstein D.S. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Appl. 653:1994;131-138.
12. Jones D.M., Arters J., Berger-Sweeney J. Carbon dioxide-induced anesthesia has no effect on brain biogenic amine concentrations in mice. Lab. Anim. Sci. 49:1999;316-318.
13. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr, Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
14. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. New Engl. J. Med. 339:1998;1044-1053.
15. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. New Engl. J. Med. 339:1998;1130-1143.
16. Le W., Conneely O.M., He Y., Jankovic J., Appel S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73:1999;2218-2221.
17. L'Hirondel M., Cheramy A., Godeheu G., Artaud F., Saiardi A., Borrelli E., Glowinski J. Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Res. 792:1998;253-262.
18. Lipska B.K., Halim N.D., Segal P.N., Weinberger D.R. Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat. J. Neurosci. 22:2002;2835-2842.
19. Maruyama K., Tsukada T., Ohkura N., Bandoh S., Hosono T., Yamaguchi K. The NGFI-B subfamily of the nuclear receptor superfamily (review). Int. J. Oncol. 12:1998;1237-1243.
20. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience. 79:1997;323-327.
21. Paulus M.P., Geyer M.A., Sternberg E. Differential movement patterns but not amount of activity in unconditioned motor behavior of Fischer, Lewis, and Sprague-Dawley rats. Physiol. Behav. 65:1998;601-606.
22. Piazza P.V., Ferdico M., Russo D., Crescimanno G., Benigno A., Amato G. The influence of dopaminergic A10 neurons on the motor pattern evoked by substantia nigra (pars compacta) stimulation. Behav. Brain Res. 31:1989;273-278.
23. Piazza P.V., Rouge-Pont F., Deminiere J.M., Kharoubi M., Le Moal M., Simon H. Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res. 567:1991;169-174.
24. Ralph R.J., Paulus M.P., Geyer M.A. Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J. Pharmacol. Exp. Ther. 298:2001;148-155.
25. Sacchetti P., Brownschidle L.A., Granneman J.G., Bannon M.J. Characterization of the 5′-flanking region of the human dopamine transporter gene. Brain Res. Mol. Brain Res. 74:1999;167-174.
26. Sacchetti P., Mitchell T.R., Granneman J.G., Bannon M.J. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J. Neurochem. 76:2001;1565-1572.
27. Sakurada K., Ohshima-Sakurada M., Palmer T.D., Gage F.H. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development. 126:1999;4017-4026.
28. Saucedo-Cardenas O., Conneely O.M. Comparative distribution of NURR1 and NUR77 nuclear receptors in the mouse central nervous system. J. Mol. Neurosci. 7:1996;51-63.
29. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., Smidt M.P., Cox J.J., De Mayo F., Burbach J.P., Conneely O.M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. USA. 95:1998;4013-4018.
30. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
31. Self D.W., Nestler E.J. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend. 51:1998;49-60.
32. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Brain Res. Rev. 31:2000;320-329.
33. Tseng K.Y., Roubert C., Do L., Rubinstein M., Kelly M.A., Grandy D.K., Low M.J., Gershanik O.S., Murer M.G., Giros B., Raisman-Vozari R. Selective increase of Nurr1 mRNA expression in mesencephalic dopaminergic neurons of D2 dopamine receptor-deficient mice. Brain Res. Mol. Brain Res. 80:2000;1-6.
34. Wagner J., Akerud P., Castro D.S., Holm P.C., Canals J.M., Snyder E.Y., Perlmann T., Arenas E. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat. Biotechnol. 17:1999;653-659.
35. Xiao Q., Castillo S.O., Nikodem V.M. Distribution of messenger RNAs for the orphan nuclear receptors Nurr1 and Nur77 (NGFI-B) in adult rat brain using in situ hybridization. Neuroscience. 75:1996;221-230.
36. Yang C.R., Seamans J.K., Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology. 21:1999;161-194.
37. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 276:1997;248-250.
38. Zetterstrom R.H., Williams R., Perlmann T., Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 41:1996;111-120.
39. Zhou Q.Y., Quaife C.J., Palmiter R.D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature. 374:1995;640-643.
40. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. USA. 98:2001;1982-1987.